Starling Oncology, Inc. Debt Securities, Available-for-sale, Amortized Cost
Starling Oncology, Inc. (DFPH) had Debt Securities, Available-for-sale, Amortized Cost of $34.88 million as of 2024-06-30, per its 10-Q filed 2024-08-13.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-03-26
- 2024-06-30: Debt Securities, Available-for-sale, Amortized Cost $34.88M.
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost $42.73M.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $72.28M.
- 2023-09-30: Debt Securities, Available-for-sale, Amortized Cost $60.21M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2024-06-30 | $34.88M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $42.73M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $72.28M 10-K · filed 2025-03-26 |
| 2023-09-30 | $60.21M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $80.63M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $99.21M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $121.10M 10-K · filed 2024-03-28 |
| 2022-09-30 | $119.83M 10-Q · filed 2022-11-09 |